Form 4: Biodesix CAO Sells Shares for Tax After RSU Vesting

Biodesix Chief Accounting Officer Chris Vazquez reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Summary

• Chris Vazquez, Chief Accounting Officer of Biodesix Inc. (BDSX), acquired 219 shares of common stock on January 15, 2026, upon the vesting of restricted stock units (RSUs).
• Following the RSU vesting, Vazquez sold 83 shares of common stock on January 16, 2026, at a weighted average price of $8.1493 per share to cover tax liabilities.
• The sale price for the tax-related disposition ranged from $8.10 to $8.28 per share.
• After these transactions, Vazquez directly beneficially owns 1,072 shares of common stock.
• The reported share numbers have been adjusted to reflect a one-for-twenty reverse stock split that became effective on September 15, 2025.
• The RSUs vest in four successive equal annual installments, measured from January 15, 2024, generally subject to continued service with the Issuer, and have no expiration date.

Sentiment

Score: 5

Explanation: This filing is neutral, detailing routine insider transactions (RSU vesting and tax-related sales) that are part of standard executive compensation. It does not provide information that would significantly alter sentiment regarding the company's operational performance or future prospects.

Positives

• The vesting of restricted stock units indicates continued employment and compensation for the Chief Accounting Officer, aligning executive interests with shareholder value.
• The officer retains a significant portion of the vested shares (136 shares from this vesting event, plus prior holdings), demonstrating ongoing equity ownership.

Negatives

• The sale of 83 shares, even for tax purposes, reduces the Chief Accounting Officer's direct beneficial ownership in the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing details a routine insider transaction for Biodesix Inc., a company operating in the biotechnology or diagnostics sector. Such filings are common across all industries as part of executive compensation and tax planning. The mention of a reverse stock split suggests the company may have been addressing share price concerns or preparing for a listing requirement, which is a broader trend observed in some smaller-cap companies.

Comparison to Industry Standards

• The vesting of restricted stock units and subsequent sale of shares for tax purposes by an executive, such as a Chief Accounting Officer, is a standard and widely accepted practice in corporate compensation across various industries, including biotechnology.
• The filing does not provide specific details on company performance or strategic initiatives that would allow for a direct comparison to industry peers or global benchmarks.
• The one-for-twenty reverse stock split, effective prior to these transactions, is a corporate action often undertaken by companies to increase their share price, meet exchange listing requirements, or improve market perception, a strategy employed by various companies across different sectors when facing similar circumstances.

Stakeholder Impact

• Shareholders: The sale of 83 shares by the Chief Accounting Officer represents a minor reduction in insider ownership, primarily for tax purposes, and is not typically interpreted as a lack of confidence. The previously effective reverse stock split would have impacted all shareholders by reducing the number of outstanding shares and proportionally increasing the per-share price.
• Employees: The RSU vesting demonstrates the company's ongoing executive compensation structure, which can be a factor in employee retention and motivation.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations. Such transactions are common and generally not indicative of a change in the company's fundamental outlook or the executive's confidence. Therefore, it provides no new information that would warrant a change in investment recommendation. An investor would typically hold their position based solely on this filing.

Keywords

Biodesix Inc., BDSX, Chris Vazquez, Chief Accounting Officer, Form 4, Insider transaction, Restricted Stock Units, RSU vesting, Stock sale, Tax withholding, Beneficial ownership, Reverse stock split